Conditions: Carcinoma, Renal Cell
Keywords: c-Met Papillary Renal Cell Carcinoma(PRC) Sporadic papillary renal cell carcinoma, Clear cell renal carcinoma Hereditary papillary renal cell carcinoma,
Allocation: NON_RANDOMIZED | Intervention model: PARALLEL
Enrollment: 74
Healthy volunteers: no

Brief summary:
This clinical study is being conducted at multiple sites to determine the best confirmed response rate, safety, and tolerability of GSK1363089 treatment in papillary renal cell carcinoma. Papillary renal cell carcinoma may be classified into hereditary and sporadic forms; subjects with either classification will be accepted into this study.

Detailed description:

Arms:
arm 1: 240 mg of foretinib on a 5 day on / 9 day off regimen every 14 days. arm 2: 80 mg foretinib on a daily dosing regimen

Interventions: intervention 1: foretinib (formerly GSK1363089 or XL880)
Intervention descriptions: intervention 1: treatment with oral foretinib on one of 2 dosing regimens: 240 mg on a 5 day on / 9 day off schedule every 14 days, or 80 mg on a daily dosing schedule

Protocol document: